[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619906":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":41,"collaborators":19,"id":43,"slug":19,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":19,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":19,"studyType":55,"phases":56,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":28,"whyStopped":19,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-Pentixafor PET\u002FCT","EXPERIMENTAL","All enrolled participants will undergo \\^68Ga-Pentixafor PET\u002FCT to evaluate CXCR4 expression patterns and assist in the differential diagnosis of ACTH-dependent and ACTH-independent subtypes. In cases where ectopic ACTH syndrome (EAS) is clinically suspected-such as in patients with inconclusive pituitary imaging or discordant biochemical profiles-an additional \\^68Ga-DOTATATE PET\u002FCT scan will be performed as part of the diagnostic workup. This allows for a head-to-head comparison between CXCR4-targeted and somatostatin receptor (SSTR)-targeted imaging modalities in the localization of ACTH-secreting tumors.",[13],"Drug: 68Ga-Pentixafor",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","68Ga-Pentixafor",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Zhaohui Zhu, MD","CONTACT","86-13611093752","13611093752@163.com",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Beijing","Beijing Municipality","100730","China",{"type":34,"coordinates":35},"Point",[36,37],116.39723,39.9075,{"lat":37,"lon":36},[40],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"type":42,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100619906",false,"NCT07350707","Diagnostic Value of CXCR4-targeted PET\u002FCT in ACTH-dependent and Independent Cushing's Syndrome","CXCR4-Targeted PET Imaging for the Differential Diagnosis of ACTH-Dependent and ACTH-Independent Cushing's Syndrome: A Prospective Observational Study","Inclusion Criteria:\n\n* Clinical suspicion or confirmed diagnosis of Cushing's syndrome, based on clinical features (e.g., central obesity, moon face, muscle weakness) and\u002For abnormal cortisol-related biochemical tests.\n* Able and willing to undergo PET\u002FCT imaging with both 68Ga-Pentixafor and, when applicable, 68Ga-DOTATATE.\n* Willing to provide informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Prior administration of therapeutic or investigational radiopharmaceuticals within 5 physical half-lives before study imaging.\n\nPregnancy or breastfeeding.\n\n* History of allergic reaction to gallium-based tracers or related compounds.\n* Clinically unstable condition or severe organ dysfunction that, in the investigator's opinion, would interfere with PET\u002FCT imaging or study participation.\n* Inability to complete both 68Ga-Pentixafor and, when applicable, 68Ga-DOTATATE PET\u002FCT imaging due to clinical or logistical reasons.","ALL","10 Years","80 Years",{"count":53,"type":54},160,"ESTIMATED","INTERVENTIONAL",[57,58],"PHASE1","PHASE2","In previous clinical practice, 68Ga-Pentixafor PET\u002FCT has demonstrated promising diagnostic utility in various neuroendocrine tumors by targeting CXCR4, a chemokine receptor overexpressed in several ACTH-secreting neoplasms. Building on this, and leveraging the Nuclear Medicine expertise at Peking Union Medical College Hospital, we aim to conduct a prospective observational study investigating the role of CXCR4-targeted PET\u002FCT imaging in patients with confirmed or suspected Cushing's syndrome. This study will focus on evaluating the capability of \\^68Ga-Pentixafor PET\u002FCT to assist in the differential diagnosis of ACTH-dependent and ACTH-independent subtypes, as well as in the localization of primary lesions in challenging cases. Imaging performance will be assessed in comparison with conventional modalities and\u002For 68Ga-DOTATATE PET\u002FCT when available.",[61],"Cushing s Syndrome",[63,64,65,61],"pentixafor","CXCR4","PET\u002FCT","2026-01-09",{"date":68,"type":69},"2026-01-20","ACTUAL",{"date":71,"type":69},"2023-06-12",{"date":73,"type":54},"2027-02-12",{"name":5,"class":6},1]